Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Younger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and c
A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati